These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 30134964)

  • 1. Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial.
    Wang Y; Kuang Y; Chen Q; Cai R
    Trials; 2018 Aug; 19(1):455. PubMed ID: 30134964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist.
    Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y
    Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
    Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A
    Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg.
    Zhu X; Ye H; Fu Y
    Fertil Steril; 2017 Feb; 107(2):379-386.e4. PubMed ID: 27865446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
    Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y
    Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial.
    Dong J; Wang Y; Chai WR; Hong QQ; Wang NL; Sun LH; Long H; Wang L; Tian H; Lyu QF; Lu XF; Chen QJ; Kuang YP
    BJOG; 2017 Jun; 124(7):1048-1055. PubMed ID: 28276192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
    Xiao ZN; Peng JL; Yang J; Xu WM
    Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progestin-primed ovarian stimulation versus GnRH antagonist protocol in poor responders: Risk of premature LH surge and outcome of oocyte retrieval.
    Kao TC; Hsieh YC; Yang IJ; Wu MY; Chen MJ; Yang JH; Chen SU
    J Formos Med Assoc; 2023 Jan; 122(1):29-35. PubMed ID: 36123235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
    Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
    Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian response and embryo ploidy following oral micronized progesterone-primed ovarian stimulation versus GnRH antagonist protocol. A prospective study with repeated ovarian stimulation cycles.
    Vidal MDM; Martínez F; Rodríguez I; Polyzos NP
    Hum Reprod; 2024 May; 39(5):1098-1104. PubMed ID: 38498835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progestin vs. Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surges in Poor Responders Undergoing
    Chen Q; Chai W; Wang Y; Cai R; Zhang S; Lu X; Zeng X; Sun L; Kuang Y
    Front Endocrinol (Lausanne); 2019; 10():796. PubMed ID: 31824419
    [No Abstract]   [Full Text] [Related]  

  • 12. Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF/ICSI compared to a GnRH antagonist protocol: A retrospective study.
    Huang P; Tang M; Qin A
    J Gynecol Obstet Hum Reprod; 2019 Feb; 48(2):99-102. PubMed ID: 30321608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
    Kuang Y; Chen Q; Fu Y; Wang Y; Hong Q; Lyu Q; Ai A; Shoham Z
    Fertil Steril; 2015 Jul; 104(1):62-70.e3. PubMed ID: 25956370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of a progestin-primed ovarian stimulation protocol with a flexible GnRH antagonist protocol in patients with polycystic ovary syndrome who are participating in an IVF programme: study protocol for a randomised controlled trial.
    Wang N; Zhu Q; Ma M; Liang Z; Tao Y; Wang Y; Kuang Y
    BMJ Open; 2020 Dec; 10(12):e038153. PubMed ID: 33268401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation.
    Zhu X; Ye H; Fu Y
    Fertil Steril; 2017 Sep; 108(3):505-512.e2. PubMed ID: 28697910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study.
    Wei LH; Ma WH; Tang N; Wei JH
    Taiwan J Obstet Gynecol; 2016 Feb; 55(1):50-4. PubMed ID: 26927248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed Start Versus Conventional GnRH Antagonist Protocol in Poor Responders Pretreated With Estradiol in Luteal Phase: A Randomized Controlled Trial.
    Maged AM; Nada AM; Abohamila F; Hashem AT; Mostafa WA; Elzayat AR
    Reprod Sci; 2015 Dec; 22(12):1627-31. PubMed ID: 26045549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial.
    Giles J; Alama P; Gamiz P; Vidal C; Badia P; Pellicer A; Bosch E
    Fertil Steril; 2021 Aug; 116(2):404-412. PubMed ID: 33814126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.